SubHero Banner
Text

Darzalex® (daratumumab) – Expanded indication

May 7, 2018 - Janssen announced the FDA approval of Darzalex (daratumumab), in combination with Velcade® (bortezomib), melphalan, and prednisone (VMP) for the treatment of patients with newly diagnosed multiple myeloma (MM) who are ineligible for autologous stem cell transplant.

Download PDF